Cargando…

Golimumab for Rheumatoid Arthritis

Since the advent of infliximab for the treatment of rheumatoid arthritis (RA), new genetically-engineered molecules have appeared. This review aims to present the current data and body of evidence for golimumab (GLM). Safety, efficacy, tolerability and immunogenicity are all being investigated, not...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pelechas, Eleftherios, Voulgari, Paraskevi V., Drosos, Alexandros A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6463251/ https://www.ncbi.nlm.nih.gov/pubmed/30897745 http://dx.doi.org/10.3390/jcm8030387

Ejemplares similares

Clinical evaluation of the safety, efficacy and tolerability of sarilumab in the treatment of moderate to severe rheumatoid arthritis
por: Pelechas, Eleftherios, et al.
Publicado: (2019)

Rheumatoid Arthritis Treatment. A Back to the Drawing Board Project or High Expectations for Low Unmet Needs?
por: Drosos, Alexandros A., et al.
Publicado: (2019)

Anti-Rheumatic Drugs May Ameliorate the Clinical Course and Outcome of COVID-19 In Rheumatoid Arthritis Patients
por: Pelechas, Eleftherios, et al.
Publicado: (2022)

A not-to-miss Cause of Severe Cervical Spine Pain in a Patient with Rheumatoid Arthritis: A Case-Based Review
por: Drosos, Alexandros A., et al.
Publicado: (2021)

Seronegative Erosive Arthritis Following SARS-CoV-2 Infection
por: Drosos, Alexandros A., et al.
Publicado: (2021)

Treatment strategies of COVID-19: A rheumatology perspective
por: Drosos, Alexandros A., et al.
Publicado: (2022)

A Case of Recalcitrant Psoriatic Arthritis to TNF Inhibitors Improved After Administration of Secukinumab, an IL-17A Inhibitor
por: Pelechas, Eleftherios, et al.
Publicado: (2017)

Anti-Rheumatic Drugs for the Fight Against the Novel Coronavirus Infection (SARSCoV-2): What is the Evidence?
por: Pelechas, Eleftherios, et al.
Publicado: (2020)

Colchicine Against SARS-CoV-2 Infection: What is the Evidence?
por: Drosos, Alexandros A., et al.
Publicado: (2022)

Long COVID from rheumatology perspective: a simple mimicker or promoter of autoimmunity?
por: Drosos, Alexandros A., et al.
Publicado: (2022)

A Patient with Symmetrical Polyarthritis. The Value of Conventional Radiography for a Correct Diagnosis
por: Drosos, Alexandros A., et al.
Publicado: (2022)

COVID-19 in patients with gout on colchicine
por: Pelechas, Eleftherios, et al.
Publicado: (2021)

Maintained Clinical Remission in Ankylosing Spondylitis Patients Switched from Reference Infliximab to Its Biosimilar: An 18-Month Comparative Open-Label Study
por: Kaltsonoudis, Evripidis, et al.
Publicado: (2019)

An uncommon presentation of Granulomatosis with Polyangiitis
por: Pelechas, Eleftherios, et al.
Publicado: (2018)

A Response to: Letter to the Editor Regarding the Article: “Colchicine Against SARS-CoV-2 Infection: What is the Evidence?”
por: Drosos, Alexandros A., et al.
Publicado: (2022)

Biologic Therapies and Autoimmune Phenomena
por: Drosos, Alexandros A., et al.
Publicado: (2021)

Comment on the Article “Adalimumab-Induced Lupus Nephritis: Case Report and Review of the Literature”
por: Drosos, Alexandros A., et al.
Publicado: (2023)

The usefulness of magnetic resonance imaging of the hand and wrist in very early rheumatoid arthritis
por: Kosta, Paraskevi E, et al.
Publicado: (2011)

Fasting mimicking diets: A literature review of their impact on inflammatory arthritis
por: Venetsanopoulou, Aliki I., et al.
Publicado: (2019)

The impact of temporal artery biopsy for the diagnosis of giant cell arteritis in clinical practice in a tertiary university hospital
por: Kaltsonoudis, Evripidis, et al.
Publicado: (2019)

Use of conventional synthetic and biologic disease-modifying anti-rheumatic drugs in patients with rheumatic diseases contracting COVID-19: a single-center experience
por: Migkos, Michalis P., et al.
Publicado: (2021)

Long-term use of adalimumab in the treatment of rheumatic diseases
por: Papagoras, Charalampos, et al.
Publicado: (2009)

Dermatomyositis sine myositis – Case presentation
por: Kaltsonoudis, Evripidis, et al.
Publicado: (2017)

Effectiveness of Golimumab in Clinical Management of Patients with Rheumatoid Arthritis
por: Shono, Eisuke
Publicado: (2013)

Predictive Factors Related to the Efficacy of Golimumab in Patients with Rheumatoid Arthritis
por: Kanbe, Katsuaki, et al.
Publicado: (2015)

A Randomized Phase IIb Study of Mavrilimumab and Golimumab in Rheumatoid Arthritis
por: Weinblatt, Michael E., et al.
Publicado: (2017)

Long-term Use of Golimumab in Daily Practice for Patients with Rheumatoid Arthritis
por: Nemoto, Tetsuya, et al.
Publicado: (2020)

Effectiveness and Safety of Golimumab for Patients ≥75 Years Old with Rheumatoid Arthritis
por: Kurosawa, Yoichi, et al.
Publicado: (2022)

Eight-year survival study of first-line tumour necrosis factor α inhibitors in rheumatoid arthritis: real-world data from a university centre registry
por: Papadopoulos, Christos G, et al.
Publicado: (2019)

Long-term effectiveness and safety of infliximab, golimumab and golimumab-IV in rheumatoid arthritis patients from a Canadian prospective observational registry
por: Rahman, Proton, et al.
Publicado: (2020)

The Effectiveness of Intravenous Golimumab Administered Directly After Infliximab in Rheumatoid Arthritis Patients
por: Bray, Vance J., et al.
Publicado: (2018)

Erratum for Long-term Use of Golimumab in Daily Practice for Patients with Rheumatoid Arthritis
por: Nemoto, Tetsuya, et al.
Publicado: (2021)

Prevalence of comorbidities in systemic sclerosis versus rheumatoid arthritis: a comparative, multicenter, matched-cohort study
por: Panopoulos, Stylianos, et al.
Publicado: (2018)

Golimumab: A novel human anti-TNF-α monoclonal antibody for the treatment of rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis
por: Kay, Jonathan, et al.
Publicado: (2010)

Golimumab for Polyarticular Juvenile Idiopathic Arthritis and Psoriatic Arthritis: Pharmacologic and Clinical Considerations
por: McIntosh, Sydney Moore, et al.
Publicado: (2023)

Clinical, Serological and Immunological Characteristics in Greek Patients with Psoriatic Arthritis: The Role of IL-17, IL-23, and Sclerostin
por: Venetsanopoulou, Aliki I., et al.
Publicado: (2020)

Persistence with golimumab in immune-mediated rheumatic diseases: a systematic review of real-world evidence in rheumatoid arthritis, axial spondyloarthritis, and psoriatic arthritis
por: Svedbom, Axel, et al.
Publicado: (2017)

Role of golimumab, a TNF-alpha inhibitor, in the treatment of the psoriatic arthritis
por: Michelon, Melissa A, et al.
Publicado: (2010)

Golimumab in combination with methotrexate in Japanese patients with active rheumatoid arthritis: results of the GO-FORTH study
por: Tanaka, Yoshiya, et al.
Publicado: (2011)

Opsonic and Antibody Responses to Pneumococcal Polysaccharide in Rheumatoid Arthritis Patients Receiving Golimumab Plus Methotrexate
por: Migita, Kiyoshi, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_g3lavfumvijhprur0eajjfv254